首页> 外文期刊>Acta bio-medica: Atenei Parmensis >Post-surgical intestinal dysbiosis: use of an innovative mixture (Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, Lactobacillus delbrueckii LDD01)
【24h】

Post-surgical intestinal dysbiosis: use of an innovative mixture (Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, Lactobacillus delbrueckii LDD01)

机译:术后肠道营养不良:使用创新的混合物(植物乳杆菌LP01,乳酸乳杆菌creemoris LLC02亚种,德氏乳杆菌LDD01)

获取原文
           

摘要

Abdominal surgery represents a high risk for hospital-acquired infections and complication that may compromise the surgery outcome. Patients with recent abdominal surgery have an intestinal dysbiosis. There is evidence that probiotics may counterbalance the impaired microbiota. Therefore, the current survey evaluated the efficacy and safety of Abincol ? , an oral nutraceutical containing a probiotic mixture with Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions of living cells), and Lactobacillus delbrueckii LDD01 (200 millions of living cells), in 612 outpatients (344 males and 268 females, mean age 58 years) undergoing digestive surgery. Patients took 1 stick/daily for 8 weeks. Abincol ? significantly diminished the presence and the severity of intestinal symptoms and improved stool form. In conclusion, the current survey suggests that Abincol ? may be considered an effective and safe therapeutic option in the management of patients undergoing digestivesurgery.
机译:腹部手术代表医院获得性感染和并发症的高风险,可能会影响手术效果。最近进行腹部手术的患者患有肠道营养不良。有证据表明益生菌可以抵消受损的微生物群。因此,本次调查评估了Abincol®的疗效和安全性。 ,在612名门诊患者中包含一种益生菌混合物,其中含有益生菌混合物与植物乳杆菌LP01(十亿个活细胞),乳酸乳杆菌cremoris LLC02亚种(八亿个活细胞)和德氏乳杆菌LDD01(两亿个活细胞)男性和268名女性,平均年龄58岁)正在接受消化外科手术。患者每天服用1根棍子,持续8周。阿宾科尔?大大减少了肠道症状的存在和严重程度,并改善了粪便形式。总之,当前的调查表明Abincol?在消化外科手术患者的治疗中可能被认为是有效且安全的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号